CCND2 amplification is an independent adverse prognostic factor in IDH-mutant lower-grade astrocytoma

Clin Neuropathol. 2021 Jul-Aug;40(4):209-214. doi: 10.5414/NP301354.
No abstract available

Publication types

  • Letter

MeSH terms

  • Astrocytoma / genetics*
  • Astrocytoma / pathology
  • Biomarkers, Tumor / genetics*
  • Brain Neoplasms / genetics*
  • Brain Neoplasms / pathology
  • Cyclin D2 / genetics*
  • Gene Amplification
  • Humans
  • Isocitrate Dehydrogenase / genetics
  • Prognosis
  • Progression-Free Survival

Substances

  • Biomarkers, Tumor
  • CCND2 protein, human
  • Cyclin D2
  • Isocitrate Dehydrogenase